{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:23:30Z","timestamp":1781763810049,"version":"3.54.5"},"reference-count":32,"publisher":"Wiley","issue":"S7","license":[{"start":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T00:00:00Z","timestamp":1480464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>BRAF mutations occur commonly in metastatic melanomas and inhibition of mutant BRAF and the downstream kinase MEK results in rapid tumor regression and prolonged survival in patients. Combined therapy with BRAF and MEK inhibition improves response rate, progression free survival and overall survival compared with single agent BRAF inhibition, and reduces the skin toxicity that is seen with BRAF inhibitor monotherapy. However, this combination is associated with an increase in other toxicities, particularly drug\u2010related pyrexia, which affects approximately 50% of patients treated with dabrafenib and trametinib (CombiDT). We provide guidance on managing adverse events likely to arise during treatment with combination BRAF and MEK inhibition with CombiDT: pyrexia, skin conditions, fatigue; and discuss management of CombiDT during surgery and radiotherapy. By improving tolerability and in particular preventing unnecessary treatment cessations or reduction in drug exposure, best outcomes can be achieved for patients undergoing CombiDT therapy.<\/jats:p>","DOI":"10.1111\/ajco.12656","type":"journal-article","created":{"date-parts":[[2016,12,11]],"date-time":"2016-12-11T23:26:22Z","timestamp":1481498782000},"page":"5-12","source":"Crossref","is-referenced-by-count":28,"title":["Optimizing combination dabrafenib and trametinib therapy in BRAF mutation\u2010positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists"],"prefix":"10.1111","volume":"12","author":[{"given":"Victoria","family":"Atkinson","sequence":"first","affiliation":[{"name":"Princess Alexandra Hospital Greenslopes Private Hospital and University of Queensland  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia Royal North Shore and Mater Hospitals The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia Royal North Shore and Mater Hospitals The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"McArthur","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre and Cabrini Health  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[{"name":"Westmead Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Millward","sequence":"additional","affiliation":[{"name":"School of Medicine and Pharmacology University of Western Australia and Sir Charles Gairdner Hospital  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Roberts\u2010Thomson","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Brady","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre and Cabrini Health  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kefford","sequence":"additional","affiliation":[{"name":"Westmead Hospital and Macquarie University  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Haydon","sequence":"additional","affiliation":[{"name":"The Alfred Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Cebon","sequence":"additional","affiliation":[{"name":"Olivia Newton John Cancer Wellness &amp; Research Centre Austin Health Melbourne  Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,30]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2015.12.008"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2015.12.010"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002011"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.8691"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70269-3"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60868-X"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203421"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412690"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406037"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.5966"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70012-9"},{"key":"e_1_2_12_14_1","doi-asserted-by":"crossref","unstructured":"HauschildA GrobJJ DemidovLVet\u00a0al. editors. An update on BREAK\u20103 a phase III randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E\u2010positive mutation metastatic melanoma (MM). ASCO Annual Meeting Proceedings;2013.","DOI":"10.1200\/jco.2013.31.15_suppl.9013"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12132"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.4118"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60898-4"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408868"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000110"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu529"},{"key":"e_1_2_12_21_1","author":"Pharmaceutical Benefits Scheme","year":"2016","journal-title":"Trametinib PBS authority"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.437"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1210093"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11814"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70413-8"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014566428"},{"issue":"2","key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1684\/ejd.2014.2512","article-title":"Clinical observation of panniculitis in two patients with BRAF\u2010mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor","volume":"25","author":"Galliker NA","year":"2015","journal-title":"Eur J Dermatol"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.0565"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7755"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.01.038"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv139"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"issue":"15","key":"e_1_2_12_33_1","first-page":"TPS9596","article-title":"Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE\u2010022)","volume":"34","author":"Long GV","year":"2016","journal-title":"ASCO Meet Abstr"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.12656","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.12656","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.12656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T16:03:36Z","timestamp":1694448216000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.12656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,30]]},"references-count":32,"journal-issue":{"issue":"S7","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1111\/ajco.12656"],"URL":"https:\/\/doi.org\/10.1111\/ajco.12656","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,30]]}}}